Elevation Oncology (ELEV) Competitors

Senti Biosciences (NASDAQ:SNTI) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.

Do institutionals & insiders hold more shares of SNTI or ELEV?

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 8.1% of Elevation Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media refer more to SNTI or ELEV?

In the previous week, Senti Biosciences had 3 more articles in the media than Elevation Oncology. MarketBeat recorded 4 mentions for Senti Biosciences and 1 mentions for Elevation Oncology. Senti Biosciences' average media sentiment score of 0.00 beat Elevation Oncology's score of -1.00 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elevation Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Does the MarketBeat Community prefer SNTI or ELEV?

Elevation Oncology received 34 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 66.10% of users gave Elevation Oncology an outperform vote while only 45.45% of users gave Senti Biosciences an outperform vote.

Company	Underperform	Outperform
Senti Biosciences	Outperform Votes 5 45.45%	Underperform Votes 6 54.55%
Elevation Oncology	Outperform Votes 39 66.10%	Underperform Votes 20 33.90%

Do analysts prefer SNTI or ELEV?

Senti Biosciences presently has a consensus price target of $12.00, indicating a potential upside of 293.44%. Elevation Oncology has a consensus price target of $3.39, indicating a potential upside of 954.74%. Given Elevation Oncology's higher probable upside, analysts clearly believe Elevation Oncology is more favorable than Senti Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Elevation Oncology	0 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.30

Which has more risk and volatility, SNTI or ELEV?

Senti Biosciences has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.

Which has better earnings & valuation, SNTI or ELEV?

Elevation Oncology has lower revenue, but higher earnings than Senti Biosciences. Elevation Oncology is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$2.56M	31.07	-$71.06M	-$10.84	-0.28
Elevation Oncology	N/A	N/A	-$45.70M	-$0.82	-0.39

Is SNTI or ELEV more profitable?

Elevation Oncology's return on equity of -59.73% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-154.84%	-77.42%
Elevation Oncology	N/A	-59.73%	-40.05%

Summary

Elevation Oncology beats Senti Biosciences on 10 of the 16 factors compared between the two stocks.